Tagrisso

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved a liquid biopsy test (a type of biopsy that uses a blood draw instead of surgery) for detecting whether patients have EGFR mutations in their metastatic lung tumors, which could help guide treatment options.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    The drug osimertinib (brand name Tagrisso) is beneficial as an adjuvant therapy—treatment given in addition to tumor-removal surgery—for patients with stage IB–IIIA non-small cell lung cancer (NSCLC) that has a mutation in the EGFR gene.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   Emma Shtivelman, PhD

    Excerpt from MedPage Today:

    “The resistance mutation-targeting EGFR inhibitor osimertinib (Tagrisso) demonstrated superior activity against central nervous system (CNS) metastases as compared with chemotherapy or nonselective EGFR inhibitors, two randomized trials of patients with lung cancer showed.

    “In a comparison involving patients with untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC), the median CNS progression-free survival (PFS) was not reached in patients who received osimertinib or a first-generation EGFR inhibitor. However, the available data favored the osimertinib arm (95% CI 16.5 months to not reached versus 13.9 months to not reached, HR 0.48, 95% CI 0.26-0.86, P=0.014). Osimertinib also led to a higher response rate.”

    Go to full article published by MedPage Today on Aug 31, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   Emma Shtivelman, PhD

    Excerpt from The ASCO Post:

    “In a planned subgroup analysis of the phase III AURA3 trial reported in the Journal of Clinical Oncology, Wu et al found that the third-generation EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) produced higher central nervous system (CNS) response rates vs platinum plus pemetrexed (Alimta) in patients with advanced EGFR T790M-positive non–small cell lung cancer (NSCLC).

    “In AURA3, 419 patients with disease progression on prior EGFR tyrosine kinase inhibitor treatment were randomized 2:1 to receive osimertinib at 80 mg once daily or platinum plus pemetrexed. The current subgroup analysis was conducted in patients with measurable or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiologic review.”

    Go to full article published by The ASCO Post on Aug 13, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.